<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="examination before they can be used in clinics [17]. Currently," exact="ganciclovir" post="is still the first treatment of choice for CMV"/>
 <result pre="[36]. However, it is not recommended to co-administer maribavir and" exact="ganciclovir" post="both in that maribavir is an inhibitor of the"/>
 <result pre="drugs because of its reduced haematotoxicity and nephrotoxicity compared with" exact="ganciclovir" post="and valganciclovir [36]. Maertens et al. used maribavir (dose-blinded)"/>
 <result pre="of its reduced haematotoxicity and nephrotoxicity compared with ganciclovir and" exact="valganciclovir" post="[36]. Maertens et al. used maribavir (dose-blinded) to treat"/>
 <result pre="least 400 mg twice daily had efficacy like that of" exact="valganciclovir" post="for removing CMV viremia. Though a higher incidence of"/>
</results>
